Literature DB >> 17372234

Haplotype-based analysis of common variation in the acetyl-coA carboxylase alpha gene and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition.

Olga M Sinilnikova1, James D McKay, Sean V Tavtigian, Federico Canzian, Deepika DeSilva, Carine Biessy, Stéphanie Monnier, Laure Dossus, Catherine Boillot, Lydie Gioia, David J Hughes, Majken K Jensen, Kim Overvad, Anne Tjonneland, Anja Olsen, Françoise Clavel-Chapelon, Véronique Chajès, Virginie Joulin, Jakob Linseisen, Jenny Chang-Claude, Heiner Boeing, Stephan Dahm, Antonia Trichopoulou, Dimitrios Trichopoulos, Maria Koliva, Kay-Tee Khaw, Sheila Bingham, Naomi E Allen, Timothy Key, Domenico Palli, Salvatore Panico, Franco Berrino, Rosario Tumino, Paolo Vineis, H Bas Bueno-de-Mesquita, Petra H Peeters, Carla H van Gils, Eiliv Lund, Guillem Pera, José Ramón Quirós, Miren Dorronsoro, Carmen Martínez García, María-José Tormo, Eva Ardanaz, Goran Hallmans, Per Lenner, Göran Berglund, Jonas Manjer, Elio Riboli, Gilbert M Lenoir, Rudolf Kaaks.   

Abstract

A key fatty acid synthesis enzyme, acetyl-CoA carboxylase alpha (ACC-alpha), has been shown to be highly expressed in human breast cancer and other tumor types and also to specifically interact with the protein coded by one of two major breast cancer susceptibility genes BRCA1. We used a comprehensive haplotype analysis to examine the contribution of the ACC-alpha common genetic variation (allele frequency >5%) to breast cancer in a case-control study (1,588 cases/2,600 controls) nested within the European Prospective Investigation into Cancer and Nutrition. We identified 21 haplotype-tagging polymorphisms efficiently capturing common variation within 325 kb of ACC-alpha and surrounding sequences using genotype data from the HapMap project and our resequencing data. We found an effect on overall risk of breast cancer in homozygous carriers of one common haplotype [odds ratio (OR), 1.74; 95% confidence interval (95% CI), 1.03-2.94]. When the data were subdivided by menopausal status, we found statistical evidence of heterogeneity for two other common haplotypes (P value for heterogeneity = 0.016 and 0.045). In premenopausal women, the carriers of these haplotypes, compared with noncarriers, had an altered risk of breast cancer (OR, 0.70; 95% CI, 0.53-0.92 and OR, 1.35; 95% CI, 1.04-1.76). These findings were not significant after adjustment for multiple testing and therefore should be considered as preliminary and evaluated in larger independent studies. However, they suggest a possible role of the ACC-alpha common sequence variants in susceptibility to breast cancer and encourage studies of other genes involved in fatty acid synthesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372234     DOI: 10.1158/1055-9965.EPI-06-0617

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  4 in total

1.  Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer.

Authors:  Shuang Xie; Feng Zhou; Jiaojiao Wang; Haiyan Cao; Yibing Chen; Xiaonan Liu; Zhaohui Zhang; Jingyao Dai; Xianli He
Journal:  World J Surg Oncol       Date:  2015-02-12       Impact factor: 2.754

2.  Genetic variants in de novo lipogenic pathway genes predict the prognosis of surgically-treated hepatocellular carcinoma.

Authors:  Hequn Jiang; Jingyao Dai; Xiaojun Huang; Yibing Chen; Ping Qu; Jibin Li; Cheng Yi; Yefa Yang; Kejing Zhang; Qichao Huang
Journal:  Sci Rep       Date:  2015-03-26       Impact factor: 4.379

Review 3.  MicroRNA-195: a review of its role in cancers.

Authors:  Wanpeng Yu; Xiao Liang; Xiangdong Li; Yuan Zhang; Zhenqing Sun; Ying Liu; Jianxun Wang
Journal:  Onco Targets Ther       Date:  2018-10-17       Impact factor: 4.147

4.  MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.

Authors:  Richa Singh; Vikas Yadav; Sachin Kumar; Neeru Saini
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.